MISSISSAUGA, ON, Jan. 20, 2012 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced it is presenting its latest line of advanced wound care and medical coating products, including ColActive® Plus Ag from January 23rd to 26th at the Annual Arab Health Congress in Dubai, U.A.E. Now in its 37th year, Arab Health provides an opportunity for the world's leading medical products manufacturers, wholesalers and distributors to meet the 65,000 medical and scientific community attendees from the Middle East and beyond.
Since announcing a multi-year distribution agreement with a Canadian distributor that will export and distribute Covalon's ColActive Plus Ag wound care dressings in certain regions of the Middle East, the interest from medical companies to introduce Covalon products to the entire region has increased significantly. ColActive Plus Ag, a patented wound dressing, is available for distribution and has been cleared for regulatory purposes in the United States, Canada and other jurisdictions. Covalon is also showcasing SurgiClear™ and IV Clear™ - breathable, clear film antimicrobial surgical wound and IV securement dressings, along with lubricious and antimicrobial coated catheters which are available for distribution in North America, Middle East and international markets.
"We are extremely excited to present at this year's Arab Health Congress," said Brian Pedlar, Covalon's Chief Executive Officer. "There has been great excitement and interest about the ColActive Plus family of advanced wound dressings from international clinicians and medical product companies who are looking to license new breakthrough products."
To learn more about Covalon's products and services, please visit us at booth SAD 58 in the Dubai World Trade Centre from January 23rd to 26th or contact Brian Pedlar, CEO Covalon Technologies Ltd. at [email protected].
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.
For further information: